Tobam Bristol Myers Squibb CO Transaction History

Tobam

$328 Million
Q4 2024

A detailed history of Tobam transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Tobam holds 116,282 shares of BMY stock, worth $6.97 Million. This represents 2.01% of its overall portfolio holdings.

Number of Shares

116,282

Previous 209,106 44.39%

Holding current value

$6.97 Million

Previous $10.8 Million 39.21%

% of portfolio

2.01%

Previous 1.97%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 28, 2025	SELL	$51.92 - $59.94 $4.82 Million - $5.56 Million	-92,824 Reduced 44.39%	116,282 $6.58 Million
Q3 2024 Oct 09, 2024	SELL	$39.66 - $51.75 $364,990 - $476,255	-9,203 Reduced 4.22%	209,106 $10.8 Million
Q2 2024 Jul 29, 2024	SELL	$40.25 - $52.99 $5.77 Million - $7.6 Million	-143,411 Reduced 39.65%	218,309 $9.07 Million
Q1 2024 May 02, 2024	SELL	$47.98 - $54.4 $8.17 Million - $9.26 Million	-170,184 Reduced 32.0%	361,720 $19.6 Million
Q4 2023 Jan 26, 2024	SELL	$48.48 - $57.85 $2.15 Million - $2.57 Million	-44,446 Reduced 7.71%	531,904 $27.3 Million
Q3 2023 Oct 31, 2023	BUY	$57.89 - $64.73 $372,637 - $416,667	6,437 Added 1.13%	576,350 $33.5 Million
Q2 2023 Jul 31, 2023	SELL	$63.71 - $70.74 $1.25 Million - $1.39 Million	-19,661 Reduced 3.33%	569,913 $36.4 Million
Q1 2023 May 03, 2023	BUY	$65.71 - $74.53 $19.6 Million - $22.2 Million	298,474 Added 102.53%	589,574 $40.9 Million
Q4 2022 Feb 02, 2023	BUY	$68.48 - $81.09 $11 Million - $13 Million	160,303 Added 122.56%	291,100 $20.9 Million
Q3 2022 Nov 02, 2022	BUY	$0.13 - $76.84 $14,789 - $8.74 Million	113,765 Added 667.95%	130,797 $9.3 Million
Q2 2022 Aug 02, 2022	BUY	$72.62 - $79.98 $441,311 - $486,038	6,077 Added 55.47%	17,032 $1.31 Million
Q1 2022 Apr 25, 2022	BUY	$61.48 - $73.72 $234,915 - $281,684	3,821 Added 53.56%	10,955 $800,000
Q2 2021 Aug 11, 2021	SELL	$61.91 - $67.42 $36,774 - $40,047	-594 Reduced 7.69%	7,134 $477,000
Q4 2020 Feb 03, 2021	SELL	$57.74 - $65.43 $3.51 Million - $3.98 Million	-60,764 Reduced 88.72%	7,728 $479,000
Q3 2020 Nov 12, 2020	BUY	$57.43 - $63.64 $149,547 - $165,718	2,604 Added 3.95%	68,492 $4.13 Million
Q2 2020 Aug 17, 2020	SELL	$54.82 - $64.09 $224,433 - $262,384	-4,094 Reduced 5.85%	65,888 $3.87 Million
Q1 2020 May 07, 2020	SELL	$46.4 - $67.43 $3.22 Million - $4.68 Million	-69,427 Reduced 49.8%	69,982 $3.9 Million
Q4 2019 Feb 10, 2020	SELL	$49.21 - $64.19 $3.64 Million - $4.75 Million	-74,000 Reduced 34.68%	139,409 $8.95 Million
Q3 2019 Nov 12, 2019	BUY	$42.77 - $50.71 $573,716 - $680,223	13,414 Added 6.71%	213,409 $10.8 Million
Q2 2019 Aug 13, 2019	SELL	$44.62 - $49.34 $4.07 Million - $4.51 Million	-91,319 Reduced 31.35%	199,995 $9.07 Million
Q1 2019 May 15, 2019	SELL	$45.12 - $53.8 $12.8 Million - $15.3 Million	-284,791 Reduced 49.43%	291,314 $13.9 Million
Q4 2018 Feb 11, 2019	SELL	$48.76 - $63.23 $14.1 Million - $18.3 Million	-289,031 Reduced 33.41%	576,105 $29.9 Million
Q3 2018 Nov 08, 2018	BUY	$55.19 - $62.25 $782,925 - $883,078	14,186 Added 1.67%	865,136 $53.7 Million
Q2 2018 Aug 03, 2018	BUY	$50.53 - $62.98 $1.15 Million - $1.44 Million	22,787 Added 2.75%	850,950 $47.1 Million
Q1 2018 May 14, 2018	SELL	$59.92 - $68.98 $6.34 Million - $7.3 Million	-105,882 Reduced 11.34%	828,163 $52.4 Million
Q4 2017 Feb 14, 2018	SELL	$59.94 - $65.35 $10.8 Million - $11.7 Million	-179,634 Reduced 16.13%	934,045 $57.2 Million
Q3 2017 Nov 14, 2017	BUY	$55.23 - $63.74 $971,495 - $1.12 Million	17,590 Added 1.6%	1,113,679 $71 Million
Q2 2017 Aug 08, 2017	BUY	N/A	1,096,089	1,096,089 $61.1 Million

Others Institutions Holding BMY

# of Institutions

2,763

Shares Held

1.57B

Call Options Held

28M

Put Options Held

28.7M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $127B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tobam, based on Form 13F filings with the SEC.

News

Stay updated on Tobam with notifications on news.

Account